← back to search

Edward Faught

Epilepsy Foundation ·
Area of research
Psychiatry and Mental health · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Epilepsy research and treatment, Pharmacological Effects and Toxicity Studies, Neuroscience and Neuropharmacology Research, and EEG and Brain-Computer Interfaces.
h-index
68
citations
14,295
works
250
NIH funding
primary concept
email

Recent publications

Treatment Response to Antiseizure Medications in People With Newly Diagnosed Focal Epilepsy
JAMA Neurology 2025cited by 10position: middledoi
Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis
Journal of Neurology 2024cited by 12position: middledoi
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records
CNS Drugs 2023cited by 24position: middledoi
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
Neurology 2022cited by 47position: middledoi
Superior Verbal Memory Outcome After Stereotactic Laser Amygdalohippocampotomy
Frontiers in Neurology 2021cited by 53position: middledoi
Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US
Neurology 2019cited by 65position: middledoi
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy
JAMA Neurology 2019cited by 46position: middledoi
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Epiliepsy currents/Epilepsy currents 2018cited by 72position: middledoi
Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis
Epilepsy & Behavior 2018cited by 65position: firstdoi
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Epiliepsy currents/Epilepsy currents 2018cited by 60position: middledoi
Risk of pharmacokinetic interactions between antiepileptic and other drugs in older persons and factors associated with risk
Epilepsia 2018cited by 27position: firstdoi
Detection of generalized tonic–clonic seizures using surface electromyographic monitoring
Epilepsia 2017cited by 104position: middledoi
What does the U.S. Medicare administrative claims database tell us about initial antiepileptic drug treatment for older adults with new‐onset epilepsy?
Epilepsia 2017cited by 24position: middledoi
Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey
Epilepsy & Behavior 2016cited by 46position: middledoi
Adherence to antiepileptic drugs among diverse older Americans on Part D Medicare
Epilepsy & Behavior 2016cited by 31position: middledoi
Descriptive epidemiology of epilepsy in the <scp>U</scp>.<scp>S</scp>. population: A different approach
Epilepsia 2015cited by 86position: lastdoi
Estimating Epilepsy Incidence and Prevalence in the US Pediatric Population Using Nationwide Health Insurance Claims Data
Journal of Child Neurology 2015cited by 44position: middledoi
Psychiatric and neurologic risk factors for incident cases of new‐onset epilepsy in older adults: Data from U.S. Medicare beneficiaries
Epilepsia 2014cited by 68position: middledoi
BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy
Expert Opinion on Investigational Drugs 2013cited by 40position: firstdoi
Tiagabine in clinical practice: effects on seizure control and behavior
Epilepsy & Behavior 2013cited by 23position: middledoi
Incidence and prevalence of epilepsy among older US Medicare beneficiaries
Neurology 2012cited by 184position: firstdoi
Adherence to antiepilepsy drug therapy
Epilepsy & Behavior 2012cited by 98position: firstdoi
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy
European Journal of Paediatric Neurology 2012cited by 85position: lastdoi
Long‐term safety and efficacy in patients with uncontrolled partial‐onset seizures treated with adjunctive lacosamide: Results from a phase III open‐label extension trial
Epilepsia 2012cited by 83position: middledoi
Recurrent mutations in<i><scp>DNAJC5</scp></i>cause autosomal dominant Kufs disease
Clinical Genetics 2012cited by 68position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David J. Thurman · Emory University5 papers (2015–2019)Jerzy P. Szaflarski · University of Alabama at Birmingham5 papers (2016–2024)Maria Pisu · University of Alabama at Birmingham5 papers (2012–2018)Roy C. Martin · University of Alabama at Birmingham5 papers (2012–2018)Joshua Richman · University of Alabama at Birmingham5 papers (2012–2018)Jacqueline A. French · Epilepsy Foundation4 papers (2013–2018)Hyunmi Kim · Stanford University4 papers (2015–2019)Sandra L. Helmers · Carl von Ossietzky Universität Oldenburg4 papers (2012–2018)Lucia Juarez · University of Alabama at Birmingham3 papers (2016–2018)Andrés M. Kanner · University of Miami3 papers (2013–2018)Chen Dai · University of Alabama at Birmingham3 papers (2016–2018) · 3 papers (2016–2018)Cynthia L. Harden · Xenon Pharmaceuticals (Canada)3 papers (2013–2018)Linda Kalilani · Triangle3 papers (2018–2019)Ellen Funkhouser · University of Alabama at Birmingham3 papers (2012–2018)Felix Rosenow · Goethe University Frankfurt2 papers (2023–2024)Pavel Klein · Mid Atlantic Epilepsy and Sleep Center2 papers (2023–2024) · 2 papers (2023–2024) · 2 papers (2023–2024)Vicente Villanueva · Fudan University2 papers (2023–2024)